Literature DB >> 2796008

Changes in aqueous flare and cells after mydriasis.

T Oshika1, S Kato.   

Abstract

The influence of a commonly used short-acting mydriatic agent, tropicamide-phenylephrine, on aqueous flare intensity and cell number was studied both in postsurgical cases and normal subjects. Measurements with a laser flare-cell meter were carried out in 40 patients who had undergone planned extracapsular cataract extraction with posterior chamber intraocular lens implantation. On the second postoperative day, 20 patients received one drop of a combined solution of 0.5% tropicamide and 0.5% phenylephrine, and the remaining patients received no mydriatic agents. Flare-cell meter measurements in the non-mydriasis group were rather difficult, and measurements in 12 out of 20 (60%) cases were discontinued. In the mydriasis group, flare intensity became significantly lower 2 hours after the application (P less than 0.01) and continued to decrease throughout the rest of the measurement period. The cell counts tended to decrease throughout the period after mydriasis and showed significantly lower values compared to the initial value (P less than 0.01). It was considered that measurements with this instrument in postoperative cases are best performed between 30 minutes to 1 hour after the application of the short-acting mydriatic agents. In normal human eyes, the effects of 0.5% phenylephrine-0.5% tropicamide, 0.4% tropicamide, and 5% phenylephrine on aqueous flare and cells were tested separately. Aqueous flare intensity was significantly decreased by tropicamide-phenylephrine at 1, 1.5 and 2 hours (P less than 0.05), by tropicamide at 1 and 1.5 hours (P less than 0.01), and by phenylephrine at 3 hours (P less than 0.01) after the application, respectively. Values returned to normal following these transient decreases.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2796008

Source DB:  PubMed          Journal:  Jpn J Ophthalmol        ISSN: 0021-5155            Impact factor:   2.447


  8 in total

1.  Measurement of aqueous cells and flare in normal eyes.

Authors:  S M Shah; D J Spalton; S E Smith
Journal:  Br J Ophthalmol       Date:  1991-06       Impact factor: 4.638

2.  Quantitative assessment of the effects of pupillary dilation on aqueous flare in eyes with chronic anterior uveitis using laser flare photometry.

Authors:  Felicia Ikeji; Carlos Pavesio; Catey Bunce; Edward White
Journal:  Int Ophthalmol       Date:  2010-05-26       Impact factor: 2.031

Review 3.  Laser flare photometry: a noninvasive, objective, and quantitative method to measure intraocular inflammation.

Authors:  Ilknur Tugal-Tutkun; Carl P Herbort
Journal:  Int Ophthalmol       Date:  2009-05-09       Impact factor: 2.031

4.  Long-term stability of uveitis with faint anterior chamber flare treated with once-daily topical ophthalmic betamethasone.

Authors:  Masahide Kawamura; Masahiro Zako
Journal:  Inflammation       Date:  2014-04       Impact factor: 4.092

Review 5.  Laser flare-cell photometer: principle and significance in clinical and basic ophthalmology.

Authors:  Mitsuru Sawa
Journal:  Jpn J Ophthalmol       Date:  2016-11-25       Impact factor: 2.447

6.  The effects of tropicamide and cyclopentolate hydrochloride on laser flare meter measurements in uveitis patients: a comparative study.

Authors:  Medine Yilmaz; Suzan Guven Yilmaz; Melis Palamar; Halil Ates; Ayse Yagci
Journal:  Int Ophthalmol       Date:  2020-11-16       Impact factor: 2.031

7.  Quantitative assessment of aqueous flare intensity in diabetes.

Authors:  T Oshika; S Kato; H Funatsu
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1989       Impact factor: 3.117

8.  Correlation between anterior chamber characteristics and laser flare photometry immediately after femtosecond laser treatment before phacoemulsification.

Authors:  M Pahlitzsch; N Torun; M L Pahlitzsch; M K J Klamann; J Gonnermann; E Bertelmann; T Pahlitzsch
Journal:  Eye (Lond)       Date:  2016-05-27       Impact factor: 3.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.